MannKind's Pediatric Pivot: A Grant-Fueled Bid to Redefine Inhaled Insulin

DANBURY, Conn. – June 23, 2026 – MannKind Corporation, a biopharmaceutical player long defined by its novel inhaled insulin Afrezza, today announced a grant from Breakthrough T1D, the influential type 1 diabetes (T1D) research and advocacy organization. On the surface, it’s a standard industry partnership: funding to support a clinical trial. But viewed through a strategic lens, this is a pivotal move in a long-running corporate saga. The grant isn't just capital; it's a significant external validation for MannKind’s high-stakes pivot toward the pediatric market, an attempt to finally unlock the commercial potential that has eluded Afrezza for over a decade.

The collaboration will support the INHALE-1ST study, a trial evaluating Afrezza in youth newly diagnosed with T1D. This comes just one month after the FDA granted Afrezza approval for general pediatric use in children aged six and older—a landmark decision that made it the first and only inhaled insulin available to this population. Together, these developments signal a calculated strategy to reposition a niche product by targeting an area of profound unmet need.

A New Breath for Pediatric Diabetes Care

For the more than 350,000 children and adolescents in the United States living with diabetes, the vast majority with T1D, the diagnosis initiates a lifetime of relentless management. The standard of care, while effective, is burdensome. It involves a constant regimen of blood glucose monitoring and multiple daily injections (MDI) of insulin or management of an insulin pump, which still requires a subcutaneous catheter. For children, this reality is often punctuated by needle aversion, pain, and the social stigma of administering treatment at school or with friends.

This is the precise pain point MannKind aims to address. Afrezza is not another injectable insulin; it’s a dry powder delivered via a small, portable inhaler at the start of a meal. Its primary value proposition in the pediatric space is the elimination of mealtime needles. This seemingly simple change could fundamentally alter the daily experience of a child with T1D, reducing the psychological and physical toll of the disease.

"Advancing therapies that can reduce the daily burden of living with type 1 diabetes is a Breakthrough T1D priority," noted Jonathan Rosen, Ph.D., the organization's Director of Research. This statement underscores the alignment between the patient community's needs and Afrezza’s potential. The ultra-rapid action of the inhaled powder, which more closely mimics the body's natural mealtime insulin response, also offers practical advantages for the unpredictable eating habits and activity levels common in childhood.

The Science and Strategy of Validation

The backing from Breakthrough T1D, formerly JDRF, is more than a financial boost; it’s a powerful endorsement from a globally recognized leader in diabetes research. The grant, awarded through its Industry Discovery and Development Partnership (IDDP) program, is designed to accelerate promising therapies. For MannKind, this co-signature lends significant credibility to its pediatric ambitions and its technology.

“This collaboration with Breakthrough T1D represents meaningful external support of both Afrezza’s potential role in transforming insulin therapy and of the INHALE-1ST trial,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “We believe this reflects growing confidence and increased interest in advancing the potential of inhaled insulin in newly-diagnosed pediatric patients.”

The INHALE-1ST trial itself is strategically designed. Unlike the INHALE-1 study that led to the recent broad pediatric approval, this trial focuses specifically on youth aged 10 to 18 at the time of their initial diagnosis. The goal is to see if introducing a less invasive, rapid-acting option from the very beginning can establish better long-term outcomes and treatment habits. The trial's primary endpoint is Time-in-Range (TIR)—the percentage of time a patient's glucose levels stay within the optimal range of 70-180 mg/dL. TIR has become the gold standard metric for modern diabetes management, offering a more nuanced view of glycemic control than the traditional HbA1c measurement. By targeting a TIR of ≥70%, the study aims to prove that Afrezza can deliver not just convenience, but superior clinical control.

Remapping Afrezza's Commercial Trajectory

To understand the significance of this pediatric push, one must look at Afrezza's history. Approved for adults in 2014, the product has faced a difficult commercial journey. Its launch was hampered by challenges, including the market failure of a previous inhaled insulin, Pfizer's Exubera, which made physicians cautious. Furthermore, Afrezza carries a boxed warning for the risk of acute bronchospasm in patients with chronic lung disease, necessitating pre-treatment lung function tests—a logistical hurdle for prescribers and patients.

As a result, Afrezza has remained a niche product, struggling to capture significant market share from the deeply entrenched ecosystem of injectable insulins and pumps. The company's stock has reflected this difficult path. The recent FDA pediatric approval was therefore a critical lifeline, opening an entirely new market where Afrezza's core benefit—no needles—resonates most powerfully. The pediatric market is not just a line extension; it's a strategic reboot.

By securing the Breakthrough T1D grant, MannKind de-risks the next phase of its pediatric strategy financially while simultaneously broadcasting a message of scientific and community validation to investors and the medical establishment. The focus on newly diagnosed patients is particularly shrewd. It targets a moment when families are overwhelmed and most open to new solutions that can ease the transition into life with a chronic illness. If MannKind can establish Afrezza as a preferred option at the point of diagnosis, it could build a loyal user base and a defensible market position that has been unattainable in the crowded adult space.

Navigating the Competitive and Regulatory Landscape

Afrezza does not enter the pediatric market unopposed. The competitive landscape is dominated by highly advanced insulin pumps and hybrid closed-loop systems that automate insulin delivery based on continuous glucose monitor (CGM) data. Likewise, ultra rapid-acting injectable insulins like Novo Nordisk's Fiasp and Eli Lilly's Lyumjev also aim to improve mealtime glucose control. Afrezza will be positioned as a complementary tool, particularly for mealtime coverage in a regimen that still requires a daily basal insulin injection.

Furthermore, the requirement for spirometry testing to rule out underlying lung conditions remains a factor. Pediatricians will need education and support to integrate this step into their workflow. However, the American Diabetes Association's recent inclusion of inhaled insulin in its 2026 Standards of Care provides crucial institutional support. For many families, the prospect of eliminating several daily injections may well outweigh the inconvenience of periodic lung function tests.

Ultimately, MannKind is making a calculated bet that the profound unmet need for less burdensome diabetes management in children will create a powerful tailwind for Afrezza. The Breakthrough T1D grant is a key piece of this puzzle, providing the resources and credibility to see if this innovative technology can finally find its moment, not by competing head-on with the entire insulin market, but by becoming an indispensable tool for its youngest and most vulnerable patients.